Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma

Next Previous
X
Search
Trial Profile

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ciforadenant (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Corvus Pharmaceuticals

    • Most Recent Events

    • 12 Nov 2024 According to a Corvus Pharmaceuticals media release, this trial is supported by data presented in November at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting highlighting the potential of ciforadenant to overcome immunotherapy resistance in metastatic castration resistant prostate cancer.
    • 12 Nov 2024 According to a Corvus Pharmaceuticals media release, the company will not be presenting this data at the GU Malignancy conference taking place in late November and will instead target a presentation sometime in 2025, because they have decided along with their partners at partners at the Kidney Cancer Research Consortium, to continue follow-up of patients on the trial before presenting the data.
    • 12 Nov 2024 According to a Corvus Pharmaceuticals media release, a total of 46 patients were enrolled in the trial by 30 Sep 2024. The analysis of the clinical trial continues to meet the threshold for efficacy and therefore enrollment continues.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top